Apellis Pharmaceuticals to Host Conference Call on Aug 8, 2022 to Discuss Second Quarter 2022 Financial Results

Rhea-AI Summary

Apellis Pharmaceuticals (Nasdaq: APLS) announced a conference call on August 8, 2022, at 4:30 p.m. ET to discuss its second quarter 2022 financial results. Investors can pre-register for the live call and access a webcast with accompanying slides on the company's website. Apellis is recognized for its leadership in complement therapeutics, having introduced the first new class of complement medicine in 15 years. The company aims to develop transformative therapies for rare, retinal, and neurological diseases.

Positive

• Leader in complement therapeutics with first new class of medicine in 15 years.
• Focus on developing transformative therapies for rare diseases.

Negative

• None.

WALTHAM, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will host a conference call and webcast to discuss its second quarter 2022 financial results on Monday, August 8, 2022 at 4:30 p.m. ET.

To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for 30 days following the event.

About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in complement, we ushered in the first new class of complement medicine in 15 years with the approval of the first and only targeted C3 therapy. We are advancing this science to continually develop transformative medicines for people living with rare, retinal, and neurological diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.

Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178

FAQ

When is the Apellis Pharmaceuticals conference call for Q2 2022 results?

The conference call is scheduled for August 8, 2022, at 4:30 p.m. ET.

How can I access the Apellis Pharmaceuticals conference call?

You can pre-register for the call online or access the live audio webcast through the company's website.

What is Apellis Pharmaceuticals known for?

Apellis Pharmaceuticals is known for being a leader in complement therapeutics and introducing the first new class of complement medicine in 15 years.

What type of diseases does Apellis Pharmaceuticals focus on?

The company focuses on rare, retinal, and neurological diseases.